GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that it has promoted Helen Thackray, M.D., to Chief Medical Officer & Vice President of Clinical Development and Brian Hahn to Chief Financial Officer.
